This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Michael Oestergaard
Senior Research Fellow at Ionis Pharmaceuticals


Michael E. Østergaard received his Master’s degree from University of Southern Denmark in 2005 and his Ph. D. from University of Idaho in 2010 working on conformationally restricted nucleotides. Then he accepted a Post Doc. position at Ionis Pharmaceuticals where he designed ASOs for allele-selective targeting of huntingtin mRNA. Now Michael has worked for over 10 years at Ionis where he has helped optimize ASO design. Key contributions include development of tissue targeting ligands which significantly improve ASO activity in hepatocytes, pancreatic b-cells and skeletal muscles, development of ASO conjugates that allow radioactive imaging of ASOs in humans and use of gap modifications to improve therapeutic index.

Agenda Sessions

  • Bicyclic Peptide Ligands Targeting the Transferrin Receptor 1 Enhance Potency of RNA Therapeutics in Skeletal Muscle and Heart Tissues